Optimum Strategic Communications client, Ziylo, acquired by Novo Nordisk in deal that could exceed US$800m
Ziylo’s technology platform could accelerate the development of a groundbreaking treatment for diabetes patients
Ziylo’s technology platform could accelerate the development of a groundbreaking treatment for diabetes patients
PART TWO: The changing role of consensus
PART ONE: The changing role of Consensus. The new MiFID II rules are expected…
It is almost six months since MIFID II went live, Optimum Strategic Communications…
Building billion-dollar healthcare businesses in Europe is dependent on a number of success factors…
Global and European healthcare investors were generally optimistic feeling that money invested into the life sciences industry…
Whilst we are probably waiting for the biotech IPO cycle to bottom out in Europe, secondary financings have been going strong…
Europe is missing many companies scaled up to this market cap bracket, partly because any pretenders to the title have been acquired…
For more information about Optimum Strategic Communications, please get in touch
We'd love to hear from you...
GET IN TOUCH
© Copyright 2019 Optimum Strategic Communications All rights reserved.
8 Devonshire Square
London
EC2M 4PL
Tel: +44 (0)203 950 9144
Email: contact@optimumcomms.com